Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Biclotymol→

Biclotymol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
15686-33-6
Molecular formula
C21H26Cl2O2
Molecular weight
381.3 g/mol
Drug class
Halogenated phenolic antisepticlocal antibacterial agent
Mechanism of action
Exerts local antiseptic activity through effects on bacterial proteins and cell membranes; the precise molecular target is not fully characterised.
Indications / reported uses
  • Local symptomatic treatment of sore throat and oropharyngeal infections in countries where biclotymol lozenges or sprays are authorised; use is formulation-specific

Sources: NLM MeSH — Biclotymol · PubMed — Biclotymol antiseptic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Biclotymol Environmental Risk Assessment (ERA) (the Biclotymol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.